Sang Hyun Park
Research Subjects
Sang Hyun Park has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hyun-Dong Cho
Department of Food and Nutrition, Sunchon National University, Suncheon, Republic of Korea
3 shared publications - Kallu Golla Dinesh Yadav3 shared publications
- Seong-Min Hong
Division of Food Science and Technology, Gyeongsang National University, Jinju 52828, Republic of Korea
3 shared publications - Seul-A Seo
Cell Green Biolab Co., Ltd 06164 Seoul Korea
3 shared publications - Soo-Hyeon Heo
Cell Green Biolab Co., Ltd 06164 Seoul Korea
3 shared publications - Hee-Young Ahn
SBC Inc 55801 Namwon Korea
1 shared publication
Latest Publications
- Open Access
- 31 October 2025
- Published by The Korean Society of Food Preservation in Food Science and Preservation
- Vol. 32 (5) , 836-851
Policosanol (Reduchole22®) attenuates hypercholesterolemia via modulation of cholesterol biosynthesis and lipid metabolism in a high-fat diet-induced mouse model
Policosanol, a mixture of long-chain aliphatic alcohols derived from sugarcane, is a promising nutraceutical for lowering blood cholesterol levels. Previous studies have reported cholesterol-lowering mechanisms, such as adenosine monophosphate-activated protein kinase (AMPK) activation, HMG-CoA reductase (HMGCR) inhibition, LDL receptor upregulation, and enhanced bile acid excretion. However, the underlying mechanisms related to additional aspects of cholesterol biosynthesis and lipid metabolism have not been fully elucidated. In this study, we evaluated the cholesterol-lowering effects of policosanol (Reduchole22®), a policosanol purified from sugarcane ethanol extract, in a high-fat diet (HFD)-induced mouse model. Our in vivo results showed that policosanol significantly reduced the atherogenic index in plasma and inhibited key enzymes involved in cholesterol synthesis, including HMGCR and acetyl-CoA acetyltransferase 1 (ACAT1), in both hepatic and arterial tissues. Our results confirmed previously reported mechanisms, including significant reductions in the atherogenic index, HMGCR and acetyl-CoA acetyltransferase 1 (ACAT1) inhibition, increased ATP-binding cassette transporter G5 (ABCG5) expression, and enhanced cholesterol 7α-hydroxylase (CYP7A1) activity, thus promoting cholesterol excretion. Notably, our study uniquely elucidates policosanol’s modulation of cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase (LCAT), and paraoxonase 1 (PON1), providing deeper insights into HDL function, antioxidative defense mechanisms, and comprehensive lipid metabolism regulation. Our findings highlight policosanol as a distinct functional food ingredient for managing hypercholesterolemia and cardiovascular disease.
- 31 October 2025
- Published by The Korean Society of Food Preservation in Food Science and Preservation
- Vol. 32 (5) , 836-851
Open AccessPolicosanol (Reduchole22®) attenuates hypercholesterolemia via modulation of cholesterol biosynthesis and lipid metabolism in a high-fat diet-induced mouse model
Policosanol, a mixture of long-chain aliphatic alcohols derived from sugarcane, is a promising nutraceutical for lowering blood cholesterol levels. Previous studies have reported cholesterol-lowering mechanisms, such as adenosine monophosphate-activated protein kinase (AMPK) activation, HMG-CoA reductase (HMGCR) inhibition, LDL receptor upregulation, and enhanced bile acid excretion. However, the underlying mechanisms related to additional aspects of cholesterol biosynthesis and lipid metabolism have not been fully elucidated. In this study, we evaluated the cholesterol-lowering effects of policosanol (Reduchole22®), a policosanol purified from sugarcane ethanol extract, in a high-fat diet (HFD)-induced mouse model. Our in vivo results showed that policosanol significantly reduced the atherogenic index in plasma and inhibited key enzymes involved in cholesterol synthesis, including HMGCR and acetyl-CoA acetyltransferase 1 (ACAT1), in both hepatic and arterial tissues. Our results confirmed previously reported mechanisms, including significant reductions in the atherogenic index, HMGCR and acetyl-CoA acetyltransferase 1 (ACAT1) inhibition, increased ATP-binding cassette transporter G5 (ABCG5) expression, and enhanced cholesterol 7α-hydroxylase (CYP7A1) activity, thus promoting cholesterol excretion. Notably, our study uniquely elucidates policosanol’s modulation of cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase (LCAT), and paraoxonase 1 (PON1), providing deeper insights into HDL function, antioxidative defense mechanisms, and comprehensive lipid metabolism regulation. Our findings highlight policosanol as a distinct functional food ingredient for managing hypercholesterolemia and cardiovascular disease.
- Open Access
- 30 October 2025
- Published by The Korean Society of Food Preservation in Food Science and Preservation
- Vol. 32 (5) , 836-851
Policosanol (Reduchole22®) attenuates hypercholesterolemia via modulation of cholesterol biosynthesis and lipid metabolism in a high-fat diet-induced mouse model
Policosanol, a mixture of long-chain aliphatic alcohols derived from sugarcane, is a promising nutraceutical for lowering blood cholesterol levels. Previous studies have reported cholesterol-lowering mechanisms, such as adenosine monophosphate-activated protein kinase (AMPK) activation, HMG-CoA reductase (HMGCR) inhibition, LDL receptor upregulation, and enhanced bile acid excretion. However, the underlying mechanisms related to additional aspects of cholesterol biosynthesis and lipid metabolism have not been fully elucidated. In this study, we evaluated the cholesterol-lowering effects of policosanol (Reduchole22®), a policosanol purified from sugarcane ethanol extract, in a high-fat diet (HFD)-induced mouse model. Our in vivo results showed that policosanol significantly reduced the atherogenic index in plasma and inhibited key enzymes involved in cholesterol synthesis, including HMGCR and acetyl-CoA acetyltransferase 1 (ACAT1), in both hepatic and arterial tissues. Our results confirmed previously reported mechanisms, including significant reductions in the atherogenic index, HMGCR and acetyl-CoA acetyltransferase 1 (ACAT1) inhibition, increased ATP-binding cassette transporter G5 (ABCG5) expression, and enhanced cholesterol 7α-hydroxylase (CYP7A1) activity, thus promoting cholesterol excretion. Notably, our study uniquely elucidates policosanol’s modulation of cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase (LCAT), and paraoxonase 1 (PON1), providing deeper insights into HDL function, antioxidative defense mechanisms, and comprehensive lipid metabolism regulation. Our findings highlight policosanol as a distinct functional food ingredient for managing hypercholesterolemia and cardiovascular disease.
- 30 October 2025
- Published by The Korean Society of Food Preservation in Food Science and Preservation
- Vol. 32 (5) , 836-851
Open AccessPolicosanol (Reduchole22®) attenuates hypercholesterolemia via modulation of cholesterol biosynthesis and lipid metabolism in a high-fat diet-induced mouse model
Policosanol, a mixture of long-chain aliphatic alcohols derived from sugarcane, is a promising nutraceutical for lowering blood cholesterol levels. Previous studies have reported cholesterol-lowering mechanisms, such as adenosine monophosphate-activated protein kinase (AMPK) activation, HMG-CoA reductase (HMGCR) inhibition, LDL receptor upregulation, and enhanced bile acid excretion. However, the underlying mechanisms related to additional aspects of cholesterol biosynthesis and lipid metabolism have not been fully elucidated. In this study, we evaluated the cholesterol-lowering effects of policosanol (Reduchole22®), a policosanol purified from sugarcane ethanol extract, in a high-fat diet (HFD)-induced mouse model. Our in vivo results showed that policosanol significantly reduced the atherogenic index in plasma and inhibited key enzymes involved in cholesterol synthesis, including HMGCR and acetyl-CoA acetyltransferase 1 (ACAT1), in both hepatic and arterial tissues. Our results confirmed previously reported mechanisms, including significant reductions in the atherogenic index, HMGCR and acetyl-CoA acetyltransferase 1 (ACAT1) inhibition, increased ATP-binding cassette transporter G5 (ABCG5) expression, and enhanced cholesterol 7α-hydroxylase (CYP7A1) activity, thus promoting cholesterol excretion. Notably, our study uniquely elucidates policosanol’s modulation of cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase (LCAT), and paraoxonase 1 (PON1), providing deeper insights into HDL function, antioxidative defense mechanisms, and comprehensive lipid metabolism regulation. Our findings highlight policosanol as a distinct functional food ingredient for managing hypercholesterolemia and cardiovascular disease.
- Open Access
- 30 June 2025
- Published by The Korean Society of Food Preservation in Food Science and Preservation
- Vol. 32 (3) , 498-508
Policosanol (Reduchole22®) improves lipid profiles in HepG2 hepatocytes and Caco-2 enterocytes
Lipid metabolism disorders such as hypercholesterolemia, hyperlipidemia, and hyperglycemia collectively characterize dyslipidemia, a condition marked by an imbalance in blood lipid levels and impaired lipid homeostasis. Policosanol, a mixture of long-chain alcohols derived from sugarcane, has been reported to improve lipid metabolism, but its cellular mechanisms remain underexplored. This study investigated the effects of policosanol (Reduchole22®) extracted using ethanol on lipid metabolism in HepG2 hepatocytes and Caco-2 enterocytes. The data were compared with atorvastatin, a widely used hyperlipidemia drug. Compared to the control group, 250-500 μg/mL of policosanol significantly reduced intracellular cholesterol and lipid accumulation via downregulating SREBP, ACAT, and APOB and upregulating LDL-receptor, ABCA1, and APOA1 in HepG2 cells. In addition, treatment of policosanol (250-500 μg/mL) markedly inhibited HMG-CoA reductase and ACAT2 expression, leading to decreased cholesterol and total lipid accumulation in Caco-2 cells. Moreover, policosanol suppressed H2O2-induced LDL oxidation in HepG2 cells, resulting in potential activity in preventing dyslipidemia. These findings suggest that policosanol (Reduchole22®) mediates cholesterol metabolism through mechanisms similar to atorvastatin. Moreover, it could be applied as a functional food ingredient for hyperlipidemia management in endogenous and exogenous cholesterol metabolism, providing a beneficial alternative in the food industry.
- 30 June 2025
- Published by The Korean Society of Food Preservation in Food Science and Preservation
- Vol. 32 (3) , 498-508
Open AccessPolicosanol (Reduchole22®) improves lipid profiles in HepG2 hepatocytes and Caco-2 enterocytes
Lipid metabolism disorders such as hypercholesterolemia, hyperlipidemia, and hyperglycemia collectively characterize dyslipidemia, a condition marked by an imbalance in blood lipid levels and impaired lipid homeostasis. Policosanol, a mixture of long-chain alcohols derived from sugarcane, has been reported to improve lipid metabolism, but its cellular mechanisms remain underexplored. This study investigated the effects of policosanol (Reduchole22®) extracted using ethanol on lipid metabolism in HepG2 hepatocytes and Caco-2 enterocytes. The data were compared with atorvastatin, a widely used hyperlipidemia drug. Compared to the control group, 250-500 μg/mL of policosanol significantly reduced intracellular cholesterol and lipid accumulation via downregulating SREBP, ACAT, and APOB and upregulating LDL-receptor, ABCA1, and APOA1 in HepG2 cells. In addition, treatment of policosanol (250-500 μg/mL) markedly inhibited HMG-CoA reductase and ACAT2 expression, leading to decreased cholesterol and total lipid accumulation in Caco-2 cells. Moreover, policosanol suppressed H2O2-induced LDL oxidation in HepG2 cells, resulting in potential activity in preventing dyslipidemia. These findings suggest that policosanol (Reduchole22®) mediates cholesterol metabolism through mechanisms similar to atorvastatin. Moreover, it could be applied as a functional food ingredient for hyperlipidemia management in endogenous and exogenous cholesterol metabolism, providing a beneficial alternative in the food industry.